Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors

American Journal of Hypertension

Volumn 16, Issue 2, 2003, Pages 135-139

  Palmer, Robert ^a   Weiss, Robert ^b   Zusman, Randall M ^c   Haig, Ann ^a   Flavin, Susan ^a   MacDonald, Brian ^a  

^a GLAXOSMITHKLINE   (United States)

^b Androscoggin Cardiology Associates   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Celecoxib; Hypertension; Nabumetone

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUPROFEN; INDOMETACIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; BUTANONES; FEMALE; HUMANS; HYPERTENSION; IBUPROFEN; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES;

EID: 12244305525     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(02)03203-X     Document Type: Article

References (18)

1. Johnson AG: NSAIDs and increased blood pressure. What is the clinical significance? Drug Safety 1997;17:277-289.
2. de Leeuw PW: Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs 1996;51:179-187.
3. Shionoiri H: Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993;25:20-58.
4. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-484.
5. Johnson AG, Nguyen TV, Day RO: Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
6. Collins R, Peto R, Macmahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease, Part 2, short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.
7. Cook ME, Wallin JD, Thakur VD, Kadowitz PJ, McNamara DB, Garcia MM, Lipani JA, Poland M: Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997;24:1137-1144.
8. Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107(Suppl 6A):65-71.
9. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM: Cyclooxygenaase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
10. Rossat J, Maillard M, Nussberger J, Drower E, Brunner HR, Burnier M: Acute renal effects of selective inhibition of cyclooxygenase-2 in health salt-depleted subjects (Abstract). J Am Soc Nephrol 1998;9:346A.
11. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis G, Day R, Ferrax MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, for the VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
12. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL: Differential inhibition of human prostaglandin endoperoside H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-934.
13. Brooks SP, Adams J, Depalma PD, Webb EF, Palmer RH, Griswold DE: Renal Effects of cyclooxygenase inhibitors in volume-depleted dogs. Inflammopharmacology 2000;8:69-79.
14. Reitblat T, Zamir D, Estis L, Priluk R, Drogenikov T, Viskoper JR: The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hyperten 2002;16:431-434.
15. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39:929-934.
16. Morgan TO, Anderson A, Bertram D: Effect of indomethacin on blood pressure in elderly people with essential hypertension well contolled on amlodipine or enalapril. Am J Hypertens 2000;13:1161-1167.
17. Mene P, Puliese G, Patrono C: The effects of non-steroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol 1995;15:244-252.
18. Izzo JL, Levy D, Black HR: Importance of systolic blood pressure in older Americans. A Clinical Advisory Statement from the National Heart, Lung and Blood Institute. Hypertension 2000;35:1021-1024.